SUI Group Holdings reported Q3 2026 financial results, highlighted by $54.7 million in net gains on digital assets and receivables, primarily driven by unrealized gains in its SUI token treasury. The company reported total SUI holdings of approximately 109.3 million tokens as of November 2, 2026, as it continues to pivot toward a digital asset and AI-focused growth strategy.
Term
Q3 2026
“During the third quarter, we continued to identify opportunities to put our balance sheet to work to generate attractive, risk-adjusted returns and enhance the long-term value of our treasury. With approximately 109.3 million SUI tokens held across our treasury, lending arrangements and receivables, we have built a substantial position in the Sui ecosystem.”
NetScout Systems reported total revenue of $222.2 million for the quarter ended September 30, 2026, a slight increase from $219.0 million in the prior year. Net income grew significantly to $34.4 million compared to $25.8 million, driven by higher service revenue and reduced operating expenses.
Carriage Services reported a decrease in total revenue to $309.3 million for the nine months ended September 30, 2026, compared to $312.0 million in the prior year. Net income for the same period declined to $34.6 million from $39.2 million, while the company maintained a consistent quarterly dividend of $0.1125 per share.
For the period ending September 30, 2026, ICU Medical reported total assets of $3.94 billion and a reduction in long-term debt to $1.13 billion from $1.27 billion at year-end 2025. The company is managing risks related to a 2025 FDA Warning Letter regarding its infusion pumps and the integration of the Smiths Medical acquisition.
Solitario Resources Corp. reported a net loss of $4.65 million for the nine months ended September 30, 2026, compared to a $3.32 million loss in the prior year, primarily driven by increased exploration expenses. The company maintained a cash and short-term investment position of approximately $7.07 million to fund its core projects, including Florida Canyon, Lik, and Golden Crest.
For the three months ended September 30, 2026, Funko reported net sales of $258.3 million and net income of $7.5 million, a significant improvement from the $0.9 million net income in the prior year period. For the nine-month period, the company returned to profitability with a net income of $4.8 million compared to a net loss of $68.1 million in 2025, driven by reduced cost of sales and improved operating margins.
Pacira BioSciences reported a significant increase in net income to $28.5 million for Q3 2026, compared to $5.4 million in Q3 2025, despite a slight decrease in total revenues to $176.7 million. The company's financial position remains stable with $1.2 billion in total assets and a reduction in long-term debt to $293.6 million.
Columbia Banking System, Inc. reported its third-quarter 2026 results, highlighting steady growth in net interest income and a stable credit quality profile. The company continues to focus on expense management and the integration of its expanded regional footprint to drive long-term shareholder value.
US Foods Holding Corp. reported net sales of $10.4 billion for the quarter ended September 26, 2026, a 2.1% increase over the prior year. Net income rose significantly to $218 million compared to $153 million in the same period of 2025, driven by higher gross profit and improved operating margins.
Hyster-Yale, Inc. filed its Form 10-Q for the third quarter of 2026, detailing the company's financial performance across its lift truck, Bolzoni, and Nuvera segments. The report highlights quarterly revenue trends, operating margins, and management's assessment of market demand and supply chain stability.
Dana Inc. reported net sales of $2,038 million for the third quarter of 2026, up from $1,917 million in 2025. The company completed the sale of its Off-Highway business on January 1, 2026, resulting in a significant net income from discontinued operations of $1,124 million for the first nine months of the year.
Mercer International reported a net loss of $59.2 million for the third quarter of 2026, an improvement from the $80.8 million loss in the prior year period despite a slight decline in revenues to $440.7 million. The company's financial position tightened significantly, with total shareholders' equity turning to a deficit of $158.2 million as of September 30, 2026, compared to a positive $68.1 million at the end of 2025.
Playboy, Inc. reported net revenues of $31.7 million for the quarter ended September 30, 2026, a 9.4% increase year-over-year. The company achieved a net income of $1.9 million for the quarter, a significant improvement compared to the $16.3 million net loss reported for the nine-month period ending the same date.
Clarus Corp reported a return to profitability for the quarter ended September 30, 2026, with net income of $3.3 million compared to a net loss of $1.6 million in the prior year. Total sales grew to $71.2 million, driven by domestic growth, while operating expenses decreased due to lower legal costs and selling expenses.
CNL Strategic Capital, LLC reported its quarterly financial results for the period ended September 30, 2026, focusing on its portfolio of middle-market private companies. The filing details the company's net investment income and updates to its net asset value (NAV) per share, reflecting ongoing investment activity and valuation adjustments.
Trustmark Corp reported its third-quarter results for 2026, highlighting stable net interest margins and continued growth in its loan portfolio. The company noted a slight increase in non-interest expense due to technology investments, while maintaining strong capital ratios and credit quality.
Bark, Inc. reported a net loss of $3.1 million for the six months ended September 30, 2026, a significant improvement from the $17.7 million loss in the prior year period. Net revenue decreased from $209.8 million to $166.4 million year-over-year, while the company noted uncertainty regarding public proposals for a possible 'going private' transaction.
Oncor Electric Delivery Company LLC reported its quarterly results for the period ended September 30, 2026, highlighting continued investment in transmission and distribution infrastructure to support Texas grid reliability. The filing reflects stable operating revenues and net income consistent with regulatory rate structures and customer growth.
Alpha Teknova reported a 22% increase in revenue for the third quarter of 2026 compared to the prior year, reaching $12.7 million. While the company continues to operate at a net loss, it improved its quarterly net loss from $4.3 million in 2025 to $3.5 million in 2026, driven by higher gross profits and controlled operating expenses.
Nkarta, Inc. reported third quarter 2026 financial results, highlighting a net loss of $33.3 million and a cash position of $216.0 million. The company announced that initial clinical data for its NKX019 cell therapy in myositis and systemic sclerosis will be presented at the ACR Convergence 2026 conference in November. Management expects its current cash runway to fund operations into 2029.
Term
Q3 2026
“NKX019 is advancing in our two lead indications, myositis and systemic sclerosis. We’re delighted to have been selected to present our initial clinical data in two oral presentations and one poster presentation at ACR Convergence 2026 in Orlando. We believe that the safety profile of engineered CAR-NK cells could broaden cell therapy access to reach far more patients. With off-the-shelf availability and outpatient dosing at a growing network of community-based sites, our program is designed to deliver on that potential.”
Paul J. Hastings, Chief Executive Officer of Nkarta
Concentra reported Q3 2026 revenue growth of 8.6% to $622.1 million and a 36.5% increase in net income attributable to the company. Alongside the results, the board authorized a new $250 million share repurchase program and declared a quarterly cash dividend of $0.0625 per share.
“Concentra delivered another strong quarter, reflecting the consistency of our operating model and the strength of our team. Over the past 50 years, we have built a market-leading occupational health company with a clear strategy for growth. With Matt assuming the CEO role, Concentra enters its next chapter with strong momentum, an experienced leadership team and significant opportunities to expand our reach and serve more employers and patients.”
Keith Newton, executive chairman of the Board
“Our third-quarter results demonstrate our ability to translate strong operating performance into profitable growth. We expanded our footprint, strengthened the balance sheet and returned capital to shareholders. The increase in full-year guidance reflects confidence in Concentra’s performance and continued momentum. Our focus remains on disciplined growth, operational excellence and delivering high-quality care while creating long-term value for customers, patients and shareholders.”
Matt DiCanio, president and chief executive officer
CN Healthy Food Tech Group Corp. reported a significant decrease in net income for the nine months ended September 30, 2026, falling to $2.6 million from $7.0 million in the prior year period. The company is currently facing a trading halt on the Nasdaq Capital Market and is dealing with defaults under promissory notes issued during its 2025 business combination.
Alerus Financial Corp reported total assets of approximately $576 million as of September 30, 2026, compared to $517 million at year-end 2025. The company noted significant adjustments in credit loss expenses related to off-balance sheet credit exposure and HTM investment securities across multiple reporting periods.
LB Pharmaceuticals Inc. reported continued clinical development of its lead candidate, LB-102, for the treatment of schizophrenia. The company recorded a net loss for the quarter, typical for a clinical-stage biopharmaceutical firm, with research and development expenses remaining the primary driver of cash outflow.
Eton Pharmaceuticals reported a significant increase in net revenues to $57.9 million for the third quarter of 2026, driven by strong product sales. The company achieved a net income of $35.2 million for the quarter, aided by a $12.9 million income tax benefit related to the reversal of a deferred tax asset valuation allowance.
CareCloud, Inc. reported 42,548,859 shares of common stock outstanding as of October 31, 2026. The filing highlights risks related to international operations in Pakistan and Sri Lanka, the integration of several recent acquisitions including Medsphere Systems Corporation, and the ongoing incorporation of AI into their healthcare technology products.
Coty Inc. reported net revenues of $1,555.2 million for the quarter ended September 30, 2026, a slight decrease from $1,577.2 million in the prior year. Despite the revenue dip, net income attributable to Coty Inc. rose significantly to $109.5 million compared to $67.9 million in 2025, driven by lower interest expenses and favorable other income.
Ameren Corporation reported Q3 2026 GAAP diluted EPS of $2.42, up from $2.35 in the prior year, driven by infrastructure investments and higher electric retail sales due to warmer temperatures. The company raised its full-year 2026 earnings guidance and established a 2027 guidance range of $5.70 to $5.90 per diluted share.
Term
Q3 2026
“Our third-quarter results were driven by continued execution of our strategy and disciplined investment in critical energy infrastructure to deliver reliable energy for our customers at the lowest cost possible. We are well positioned to meet growing energy needs, support significant economic development across our region and deliver lasting benefits for the customers and communities we serve.”
Martin J. Lyons, Jr., chairman, president and chief executive officer
Clean Energy Fuels Corp. reported a significant reduction in net loss for the nine months ended September 30, 2026, at $29.5 million compared to $179.4 million in the prior year, largely due to the absence of a $64.3 million goodwill impairment and lower depreciation. Total revenue grew to $336.1 million for the first nine months of 2026, driven by increases in both product and service revenue.
BioAge Labs reported third quarter 2026 financial results, highlighting the dosing of the first participant in its Phase 2 QUELL-DME trial for diabetic macular edema. The company also completed enrollment in its Phase 2 QUELL-CV trial for obesity and inflammation, with topline data expected in Q4 2026.
Term
Q3 2026
“NLRP3 is a key switch that turns on inflammation and drives multiple diseases. Injectable drugs that block two major inflammatory signals, IL-1 and IL-6, are already approved for multiple indications, but a once-daily pill that works earlier in the process—and also lowers IL-18 and reduces harmful inflammatory cell death—could help many more people. That is the opportunity we are pursuing with BGE-102.”
Kristen Fortney, Ph.D., CEO and co-founder of BioAge